Results 171 to 180 of about 20,886 (213)

Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management

Annals of Pharmacotherapy, 2023
Objective: To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM). Data Sources: A literature search was conducted on PubMed from origin to
Alyssa Sykuta, Connie H. Yoon, Sarah Baldwin, Natalie I. Rine, Michael Young, Adam Smith   +5 more
openaire   +2 more sources

Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy

Cardiology in Review, 2023
Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in
Jay, Patel, Andy, Wang, Srihari S, Naidu, William H, Frishman, Wilbert S, Aronow   +4 more
openaire   +2 more sources

Cardiac Myosin Inhibitors: Unlocking Potential to Improve Treatment in Hypertrophic Cardiomyopathy

Circulation, 2023
Andrew Wang
exaly   +3 more sources

Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy

Annals of Pharmacotherapy, 2022
Objective: To assess mavacamten’s role in hypertrophic cardiomyopathy treatment. Data Sources: In addition to clinical guidelines, package inserts, and general reviews, we searched PubMed using the term mavacamten from inception to ...
Joseph D. Dalo, Nissen D. Weisman, C. Michael White   +2 more
openaire   +2 more sources

Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy

Current Opinion in Cardiology, 2023
Purpose of review Cardiac myosin inhibitors (CMIs) represent a major milestone in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The objective of this review is to discuss the mechanisms of action, clinical trial evidence, safety profile and monitoring of CMIs, which are important to the ...
Safia, Chatur, Sheila M, Hegde
openaire   +2 more sources

Cardiac Myosin Inhibitors for the Treatment of Obstructive and Non-Obstructive HCM

Nature Reviews Cardiology
Karina Huynh
exaly   +3 more sources

Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors

Journal of Cardiothoracic and Vascular Anesthesia
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. The disease is characterized by asymmetric left ventricular (LV) remodeling with myocyte disarray and interstitial fibrosis, a hypercontractile state, dynamic subaortic obstruction of the LV outflow tract, impaired LV diastolic function, atrial and ventricular arrhythmias ...
Paul S, Pagel, Dustin, Hang, Julie K, Freed, George J, Crystal   +3 more
openaire   +2 more sources

The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy

Canadian Journal of Cardiology
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy worldwide and causes significant morbidity and mortality. For decades, medical treatment options have been limited and untargeted, with frequent need for invasive interventions not readily accessible to many HCM patients.
Rebecca Haraf, Hany Habib, Ahmad Masri
openaire   +2 more sources

Mechanisms of a Novel Regulatory Light Chain–Dependent Cardiac Myosin Inhibitor

Journal of General Physiology
Hypertrophic cardiomyopathy (HCM) is a genetic disease of the heart characterized by thickening of the left ventricle (LV), hypercontractility, and impaired relaxation. HCM is caused primarily by heritable mutations in sarcomeric proteins, such as β myosin heavy chain.
Timothy S McMillen, Michael Regnier, Na Sa   +2 more
exaly   +3 more sources

Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy

Med
A key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these
Milind Y, Desai, Eugene, Braunwald
openaire   +2 more sources